GLP-1 sleep changes run both ways; the firmest evidence is for sleep apnoea.
- In two year-long trials, tirzepatide cut apnoea events by 25 to 29 an hour, against about 5 on placebo.
- Neither the Wegovy nor the Zepbound label lists insomnia; forums mostly report 3am waking.
- Lasting insomnia calls for CBT for insomnia, ahead of sleep tips alone.

GLP-1 sleep changes don’t get much airtime next to nausea or appetite. They should. Poor sleep raises cortisol and increases hunger signalling. In a 1999 study in The Lancet, six nights of four hours in bed raised evening cortisol in 11 young men, compared with the same men after recovery sleep. In a 2004 report of 12 healthy young men in the Annals of Internal Medicine, two nights of restricted sleep raised the hunger hormone ghrelin by 28% and self-rated hunger by 24%, against two nights of longer sleep.
If your sleep has shifted since starting treatment, here’s what the trials and the drug labels say is driving it, and what you can do about it.
Table of Contents
Why Does GLP-1 Medication Affect Sleep?
GLP-1 medication can affect sleep through its side effects, and possibly through the brain, where its receptors also sit. A 2021 systematic review in Frontiers in Behavioral Neuroscience, which pulled together about a hundred studies, describes them as widely found in the brain, including its reward areas, though most of what it gathered comes from animal studies. What that means for sleep in people taking semaglutide or tirzepatide is thin on human evidence.
The practical routes are easier to see. Both drugs slow how fast the stomach empties, so a meal eaten late takes longer to clear and can still be sitting there when you lie down. Nausea is the most common side effect: 44% on Wegovy against 16% on placebo in its weight-loss trials, and 25% to 29% on Zepbound against 8% in Zepbound’s trials. For people with diabetes, steadier blood sugar overnight could help sleep, though that is a plausible route rather than a measured one.
Vivid dreams come up in forum threads as one-offs.
What the two drug labels leave out of their side effect lists matters as well. Neither the Wegovy nor the Zepbound prescribing information mentions insomnia. Fatigue is listed: 11% on Wegovy against 5% on placebo in Wegovy’s prescribing information, and 5% to 7% on Zepbound against 3% in Zepbound’s. So tiredness in the day is a recorded side effect. Sleeplessness at night is not.
Can GLP-1 Medication Improve Sleep Apnoea?
One of the clearest GLP-1 sleep benefits is in obstructive sleep apnoea, where the airway keeps closing during sleep. Excess body fat is a major reversible risk factor for it, and the benefit of substantial weight loss is well recognised, according to the authors of the tirzepatide trials. Zepbound (tirzepatide) is FDA-approved to treat moderate to severe obstructive sleep apnoea in adults with obesity, which is why the guide to Zepbound sleep apnoea coverage finds plans that exclude weight loss may still cover it for that use.
Research published in the New England Journal of Medicine found that tirzepatide reduced sleep apnoea severity in 469 adults who had obesity and moderate-to-severe obstructive sleep apnoea. It was two 52-week trials, split by whether people were already on PAP therapy (positive airway pressure, which includes CPAP), and people with type 2 diabetes were left out. The mean fall was 25.3 apnoea events an hour in the group not on PAP and 29.3 in the group on it, against 5.3 and 5.5 on placebo.
Weight fell by 17.7% and 19.6%, against 1.6% and 2.3% on placebo, according to the Zepbound label, so the weight loss in those results was substantial rather than incidental. Eli Lilly, which makes tirzepatide, funded both trials.
Those are 52-week figures and, per the trial report, the only earlier sleep study was at week 20, so readers who describe sleeping more deeply in the first few weeks are describing something neither trial measured. By week 52, 42% and 50% on tirzepatide had reached remission or mild apnoea without daytime sleepiness, against 16% and 14% on placebo. People on tirzepatide also reported less sleep-related impairment, though the authors say the smallest change that matters to patients on those scales has not been set.
If you were diagnosed with sleep apnoea and use a CPAP machine, bring your GLP-1 progress to the doctor who manages it. Pressure settings calibrated for your previous weight may need reviewing. The Zepbound label notes that the trials did not test when, or whether, someone already on PAP therapy, such as CPAP, should stop, so that call stays with your sleep doctor.
Why Do Some People Develop Insomnia on GLP-1 Medication?
Some people sleep worse on GLP-1 medication, most often in the early weeks of treatment or after a dose increase, by their own reports. They describe difficulty falling asleep, staying asleep, or both.
A few factors likely contribute. Nausea is the most common side effect of GLP-1 medication, and nausea at night makes it harder to relax into sleep. The slowed stomach emptying that reduces appetite can also cause bloating or discomfort when lying flat. A 2024 commentary in Diabetes, Metabolic Syndrome and Obesity advises small, frequent meals and not lying down after eating; one of its authors is affiliated with Novo Nordisk, which makes Wegovy.
The sleep complaint named most often in forum threads is waking at 2 or 3am, often at the same time each night. A visible minority say they sleep better on the drug. The threads name their own confounders: getting up to urinate after drinking more water, perimenopause and menopause, and pets. Their favourite explanation is an overnight dip in blood sugar, which stays a forum theory.
If you’re in perimenopause or menopause, hormones can break sleep on their own, whatever the medication is doing. Marilyn Luis, a nutrition specialist, covers that side in why sleep gets worse in menopause, including when snoring means asking for a sleep study.
If you have type 2 diabetes, rule out low blood sugar. The Wegovy label calls it a serious and common side effect for people with type 2 diabetes, especially those who also take insulin or a sulfonylurea, and its signs include sweating, shakiness, a fast heartbeat, confusion and hunger. If you wake with those, check your blood sugar and tell your prescriber.
Does Injection Timing Affect Sleep on GLP-1 Medication?
It may, for some people. Forum reports put the worst nights soon after the shot, and both labels leave the time of day up to you. Wegovy and Zepbound injections are once a week, at any time of day, with or without meals. The Wegovy tablet is taken daily.
The drug peaks in the blood one to three days after a semaglutide shot, and a median of 24 hours after a tirzepatide shot (anywhere from 8 to 72 hours), according to Wegovy’s label and Zepbound’s. Forum reports put the worst symptoms one to four days after the shot, and some describe a sleepless night on shot night itself. Neither label ties side effects to that peak, so treat them as two separate facts.
If you inject on a Thursday evening and your worst nights are Thursday and Friday, the timing may be part of it. Wegovy’s label lets the time of day change without changing the dose, and the day change if your last dose was at least two days earlier. Zepbound’s needs at least 3 days (72 hours) between doses. Some users find a morning slot, or a day when a poor night costs less, makes a difference. Check with your prescriber before you move it.
Do Hunger Hormones Change Sleep on GLP-1 Medication?
Ghrelin, the hormone most associated with hunger signalling, also plays a role in sleep. A trial in the American Journal of Physiology gave seven healthy men ghrelin by injection across the evening and measured more slow-wave (deep) sleep over the night, with less REM in the middle third; cortisol rose early in the night too. Seven people, all young men at a normal BMI, and injected ghrelin rather than anything a GLP-1 drug does. Read it as the mechanism, not as a finding about this drug or about the people taking it.
Whether GLP-1 drugs lower ghrelin at all is not settled. In one small trial, a single dose of liraglutide, an older daily GLP-1 drug, lowered ghrelin over five hours in adults with type 1 diabetes (Diabetes, Obesity and Metabolism). In a 12-week pilot in adults with obesity and binge eating, ghrelin went up on liraglutide (Obesity Research & Clinical Practice). Neither measured sleep, and neither tested semaglutide or tirzepatide.
So when GLP-1 users say they feel less rested after the same number of hours, a change in how deep their sleep runs is one possible explanation. None of these studies measured it on these drugs.
How Do You Improve Sleep on GLP-1 Medication?
If your sleep has worsened since starting medication, try these targeted changes before assuming the disruption is permanent. The table sets each complaint against what the evidence shows.
| GLP-1 sleep complaint | What the evidence shows | What to try first |
|---|---|---|
| Sleep apnoea | Tirzepatide trials: 25 to 29 fewer events an hour at 52 weeks, against about 5 on placebo | Talk to your sleep doctor; don’t change CPAP on your own |
| Waking at 2 to 3am | Forum reports only; neither label lists it | A small bedtime snack or a morning shot, as users try; check blood sugar if you have type 2 diabetes |
| Nausea or reflux at night | Nausea is the most common label side effect | A gap between dinner and bed; smaller, less fatty evening meals |
| Tired in the daytime | Fatigue: 11% on Wegovy against 5%; 5% to 7% on Zepbound against 3% | Tell your prescriber if it lasts |
| Insomnia that lasts | CBT for insomnia strongly recommended by the sleep medicine guideline | Ask about CBT for insomnia, not sleep tips alone |
Leave a gap between dinner and bed. Food clears the stomach more slowly on GLP-1 medication, so what was fine to eat at 8pm before may still be there when you lie down. The Diabetes, Metabolic Syndrome and Obesity commentary advises against lying down after meals, and the joint advisory from four US obesity and nutrition societies notes that vomiting is more likely after large meals and that smaller, more frequent meals can help with nausea. Neither gives a number of hours, so start at about three and adjust.
Watch what you eat in the evening. Fatty or heavily seasoned food takes longer to clear, and a light, protein-forward evening meal tends to sit better. In forum threads, a small bedtime snack is the most common fix for the 3am wake-up, with a protein camp and a carb camp. That is a forum pattern, and no trial has tested it.
Consider magnesium glycinate, with modest expectations. The glycinate form has one trial behind it and the result is modest. A 2025 randomised trial in Nature and Science of Sleep split 155 healthy adults who reported poor sleep between 250 mg of elemental magnesium a day as bisglycinate and dummy capsules (a placebo). Insomnia scores fell further on magnesium over four weeks, by 3.9 points against 2.3. The effect size was small and the authors say so; average scores at four weeks still sat in the subthreshold band, below clinical insomnia but not gone.
The trial left out anyone with a diagnosed sleep disorder such as sleep apnoea, a chronic illness needing treatment, or a BMI over 35, so it says nothing direct about people taking a GLP-1 drug for weight. Magnesium may calm the nervous system through GABA, the brain’s main calming messenger, but that idea comes from lab and animal work. The magnesium section of the GLP-1 supplements guide covers which forms the NIH lists as best absorbed (glycinate is not one), the 350 mg a day upper limit for supplements, and why kidney disease means asking first. Discuss it with your doctor or pharmacist before adding any new supplement.
Keep injection day consistent. Wegovy’s label asks for the same day each week. A fixed day also makes it easier to see whether your worst nights follow your shot, so pick a day that works week to week and stick to it.
Limit alcohol. Alcohol disrupts sleep architecture even in small amounts, and the joint advisory notes it may worsen nausea and reflux on GLP-1 therapy, which the guide to alcohol on GLP-1 medication for social drinkers works through drink by drink. Semaglutide may also change how much some people drink. In a 2025 randomised trial in JAMA Psychiatry, 48 non-treatment-seeking adults with alcohol use disorder were split between low-dose semaglutide and placebo for nine weeks. The semaglutide group drank less on the days they drank and reported less craving. The number of drinking days did not move.
Check your caffeine. New sensitivity to caffeine comes up in the same forum threads as the 3am waking. If an afternoon coffee now keeps you up, the section on coffee and sleep on GLP-1 is the place to start.
Track your sleep patterns. If you’re not sure whether your sleep has changed or by how much, a basic sleep tracking app or wearable gives you something concrete to work with. Logging nights against your shot day in the GLP-1 side effects tracker makes patterns clearer across a few weeks than memory does.
What Helps If GLP-1 Insomnia Doesn’t Settle?
Most of those changes are sleep hygiene. For insomnia that has become chronic, the American Academy of Sleep Medicine’s 2021 guideline strongly recommends cognitive behavioural therapy for insomnia (CBT-I), a structured programme that works on the habits and thoughts that keep you awake. It suggests against using sleep hygiene on its own as the treatment. Its weaker suggestions include shorter structured programmes and single techniques such as relaxation training.
The guideline is written for adults with chronic insomnia in general rather than for GLP-1 users, and it does not cover peptides sold for sleep; the Epitalon and sleep page sets out what the FDA found when it reviewed Epitalon for insomnia.
Mood and sleep often move together. If low mood or anxiety is part of what keeps you up, the mental health guide’s section on what to do when mood changes are affecting you sets out what to tell your prescriber and how to add a therapist, including a CBT-based online option with a weekly live session.
When Should You Talk to Your Doctor About GLP-1 Sleep Problems?
See your prescribing doctor if insomnia persists, if sleep consistently deteriorates after dose increases, or if you notice new symptoms like restless legs or significantly disrupted breathing during sleep. Disrupted sleep in the early weeks is a common forum report, and many describe it settling as the body adjusts.
Don’t stop or adjust your medication without medical guidance. A conversation about timing, dose, or supportive strategies is the next step.
What This Means for Your Sleep on GLP-1
GLP-1 sleep changes go in both directions. In the tirzepatide trials, people with obesity and sleep apnoea had far fewer breathing pauses an hour. People who get nausea or stomach discomfort in the early weeks may go through a period of worse sleep before it stabilises.
What’s clear is that sleep quality matters for the outcomes you’re trying to achieve. Poor sleep raises cortisol and increases hunger signalling. More hunger plausibly makes a calorie deficit harder to hold, though neither sleep study cited here measured what people ate. Protecting your sleep is part of getting the most from your medication.
If you’re also trying to get your nutrition right during this phase, the GLP-1 Protein Calculator and GLP-1 Meal Plan tools are a practical place to start.
Get free GLP-1 tools and guides
The free tools and the guides worth reading first, so you know where to start without digging through the site. No spam, ever.
References
- Novo Nordisk. Wegovy (semaglutide) prescribing information. DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
- Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine, 2024. Funded by Eli Lilly. doi.org/10.1056/NEJMoa2404881
- Eren-Yazicioglu CY, et al. Can GLP-1 Be a Target for Reward System Related Disorders? A Qualitative Synthesis and Systematic Review Analysis. Frontiers in Behavioral Neuroscience, 2021. doi.org/10.3389/fnbeh.2020.614884
- Gentinetta S, et al. Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist. Diabetes, Metabolic Syndrome and Obesity, 2024. One author is affiliated with Novo Nordisk; editorial help was funded by a Novo Nordisk grant. doi.org/10.2147/DMSO.S494919
- Mozaffarian D, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Lifestyle Medicine, 2025. pmc.ncbi.nlm.nih.gov/articles/PMC12125019
- Spiegel K, Leproult R, Van Cauter E. Impact of sleep debt on metabolic and endocrine function. The Lancet, 1999. doi.org/10.1016/S0140-6736(99)01376-8
- Spiegel K, et al. Brief communication: Sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Annals of Internal Medicine, 2004. doi.org/10.7326/0003-4819-141-11-200412070-00008
- Weikel JC, et al. Ghrelin promotes slow-wave sleep in humans. American Journal of Physiology: Endocrinology and Metabolism, 2003. doi.org/10.1152/ajpendo.00184.2002
- Garg M, et al. Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes. Diabetes, Obesity and Metabolism, 2017. doi.org/10.1111/dom.12944
- Robert SA, et al. Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide: a pilot study. Obesity Research & Clinical Practice, 2015. doi.org/10.1016/j.orcp.2015.03.005
- Schuster J, et al. Magnesium Bisglycinate Supplementation in Healthy Adults Reporting Poor Sleep: A Randomized, Placebo-Controlled Trial. Nature and Science of Sleep, 2025. Funded by Leibniz University Hannover; one author runs a research company funded by supplement makers. doi.org/10.2147/NSS.S524348
- Hendershot CS, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 2025. doi.org/10.1001/jamapsychiatry.2024.4789
- Edinger JD, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 2021. doi.org/10.5664/jcsm.8986
